Franz Humer
Franz Humer
Franz Bernhard Humer is a Swiss-Austrian businessman, the chairman of Diageo, and of Roche...
amount became difficult invested less sales sat
It became a drug which was difficult to commercialize, ... We sat there with a drug in which we had invested a significant amount of development and where we had sales that were less than exciting.
demand facility importance increasing market respond utmost
It is of utmost importance to have a facility that can respond to the increasing market demand for our PCR products.
continued drivers growth last strong
All growth drivers continued last year's strong performance.
additional cancer division gained major market products strong
Our pharmaceuticals division gained additional market share, with all major products contributing to this strong performance, particularly our new cancer medicines,
licensed maintain manage organic product stance
If I look at what we have in the product pipeline, and what we have licensed in, I maintain our stance that we can manage with organic growth.
mankind patents producing stand
Patents will not stand in the way of producing the drug for mankind.
half line second
I would say that we would see an acceleration (in drug sales), especially in the second half of the year, with the introduction of new products, with the acceleration also of the penetration of the oncology line in the non-U.S. markets,
anybody complement faster people talk
We will talk to anybody -- people who can manufacture the drug, and are able to manufacture it faster than us, and complement our manufacturing,